Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing enterobacteriaceae and patient outcome: A meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 6, 2012, Pages 1311-1320

  Rottier, Wouter C ^a   Ammerlaan, Heidi S M ^a   Bonten, Marc J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Empirical therapy; Statistical adjustment; Subgroup analysis

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL VIRULENCE; DISEASE ASSOCIATION; DISEASE SEVERITY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; GERIATRIC PATIENT; HOSPITAL INFECTION; HUMAN; META ANALYSIS; MORTALITY; NONHUMAN; RISK FACTOR; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME;

BACTEREMIA; BETA-LACTAMASES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MODELS, STATISTICAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84861109391     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks065     Document Type: Article

References (47)

1. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med 2006; 119 Suppl 1: S20-8.
2. Pitout JD. Infections with extended-spectrum β-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010; 70: 313-33.
3. Blot S, Depuydt P, Vandewoude K et al. Measuring the impact of multidrug resistance in nosocomial infection. Curr Opin Infect Dis 2007; 20: 391-6.
4. McGregor JC, Rich SE, Harris AD et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 2007; 45: 329-37.
5. Schwaber MJ, Carmeli Y. Antimicrobial resistance and patient outcomes: the hazards of adjustment. Crit Care 2006; 10: 164.
6. Hurley JC. Comparison of mortality associated with methicillinsusceptible and methicillin-resistant Staphylococcus aureus bacteremia: an ecological analysis. Clin Infect Dis 2003; 37: 866-8; author reply 868-9.
7. Wells GA, Shea B, O'Connell D et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (6 January 2011, date last accessed).
8. Paul M, Shani V, Muchtar E et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother 2010; 54: 4851-63.
9. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
10. Ariffin H, Navaratnam P, Mohamed M et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis 2000; 4: 21-5.
11. Blomberg B, Jureen R, Manji KP et al. High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum β-lactamases in Dar Es Salaam, Tanzania. J Clin Microbiol 2005; 43: 745-9.
12. Borer A, Gilad J, Menashe G et al. Extended-spectrum β-lactamaseproducing Enterobacteriaceae strains in community-acquired bacteremia in southern Israel. Med Sci Monit 2002; 8: CR44-7.
13. Cordery RJ, Roberts CH, Cooper SJ et al. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome. J Hosp Infect 2008; 68: 108-15.
14. Daikos GL, Kosmidis C, Tassios PT et al. Enterobacteriaceae bloodstream infections: presence of integrons, risk factors, and outcome. Antimicrob Agents Chemother 2007; 51: 2366-72.
15. Du B, Long Y, Liu H et al. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002; 28: 1718-23.
16. Endimiani A, Luzzaro F, Brigante G et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum β-lactamases. Antimicrob Agents Chemother 2005; 49: 2598-605.
17. Gudiol C, Calatayud L, Garcia-Vidal C et al. Bacteraemia due to extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010; 65: 333-41.
18. Ho PL, Chan WM, Tsang KW et al. Bacteremia caused by Escherichia coli producing extended-spectrum β-lactamase: a case-control study of risk factors and outcomes. Scand J Infect Dis 2002; 34: 567-73.
19. Kang CI, Song JH, Chung DR et al. Risk factors and treatment outcomes of community-onset bacteraemia caused by extendedspectrum β-lactamase-producing Escherichia coli. Int J Antimicrob Agents 2010; 36: 284-7.
20. Kim BN, Woo JH, Kim MN et al. Clinical implications of extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect 2002; 52: 99-106.
21. Kim YK, Pai H, Lee HJ et al. Bloodstream infections by extendedspectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002; 46: 1481-91.
22. Marchaim D, Gottesman T, Schwartz O et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 2010; 54: 5099-104.
23. Marra AR, Wey SB, Castelo A et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis 2006; 6: 24.
24. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum β-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007; 55: 254-9.
25. Memon JI, Rehmani RS, Ahmed MU et al. Extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia. Saudi Med J 2009; 30: 803-8.
26. Menashe G, Borer A, Yagupsky P et al. Clinical significance and impact on mortality of extended-spectrum b lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001; 33: 188-93.
27. Mosqueda-Gomez JL, Montano-Loza A, Rolon AL et al. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae. A case-control study. Int J Infect Dis 2008; 12: 653-9.
28. Ortega M, Marco F, Soriano A et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009; 63: 568-74.
29. Panhotra BR, Saxena AK, Al-Ghamdi AM. Extended-spectrum β-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia. Risk factors and clinical outcome. Saudi Med J 2004; 25: 1871-6.
30. Peña C, Pujol M, Ardanuy C et al. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum β-lactamase. J Hosp Infect 2001; 47: 53-9.
31. Rodríguez-Baño J, Picon E, Gijon P et al. Community-onset bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: risk factors and prognosis. Clin Infect Dis 2010; 50: 40-8.
32. Schwaber MJ, Navon-Venezia S, Kaye KS et al. Clinical and economic impact of bacteremia with extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50: 1257-62.
33. Superti SV, Augusti G, Zavascki AP. Risk factors for and mortality of extended-spectrum-β-lactamase-producing Klebsiella pneumoniae and Escherichia coli nosocomial bloodstream infections. Rev Inst Med Trop Sao Paulo 2009; 51: 211-6.
34. Szilágyi E, Fuzi M, Borocz K et al. Risk factors and outcomes for bloodstream infections with extended-spectrum β-lactamaseproducing Klebsiella pneumoniae; findings of the nosocomial surveillance system in Hungary. Acta Microbiol Immunol Hung 2009; 56: 251-62.
35. Trecarichi EM, Tumbarello M, Spanu T et al. Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 2009; 58: 299-307.
36. Tsai SS, Huang JC, Chen ST et al. Characteristics of Klebsiella pneumoniae bacteremia in community-acquired and nosocomial infections in diabetic patients. Chang Gung Med J 2010; 33: 532-9.
37. Tumbarello M, Spanu T, Sanguinetti M et al. Bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50: 498-504.
38. Tumbarello M, Spanu T, Di Bidino R et al. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-β-lactamase production and inadequate initial antibiotic therapy. Antimicrob Agents Chemother 2010; 54: 4085-91.
39. Tuon FF, Bianchet LC, Penteado-Filho SR. Epidemiology of extended spectrum β-lactamase producing Enterobacter bacteremia in a Brazilian hospital. Rev Soc Bras Med Trop 2010; 43: 452-4.
40. Zaoutis TE, Goyal M, Chu JH et al. Risk factors for and outcomes of bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 2005; 115: 942-9.
41. Paterson DL, Ko WC, Von Gottberg A et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum β-lactamase production in nosocomial infections. Ann Intern Med 2004; 140: 26-32.
42. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998; 280: 1690-1.
43. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 913-20.
44. Paul M, Kariv G, Goldberg E et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2010; 65: 2658-65.
45. Ammerlaan H, Seifert H, Harbarth S et al. Adequacy of antimicrobial treatment and outcome of Staphylococcus aureus bacteremia in 9 western European countries. Clin Infect Dis 2009; 49: 997-1005.
46. Schweizer ML, Furuno JP, Harris AD et al. Empiric antibiotic therapy for Staphylococcus aureus bacteremia may not reduce in-hospital mortality: a retrospective cohort study. PLoS One 2010; 5: e11432.
47. Marcos M, Soriano A, Martinez JA et al. Septic shock should be included in multivariable models analyzing the effect of empirical antibiotic therapy on mortality. Clin Infect Dis 2007; 45: 1401; author reply 1401-2.